Skip to main content
. 2021 Jun 12;74(5):897–900. doi: 10.1093/cid/ciab543

Table 1.

Characteristics and Outcomes of 24 Vaccine-Breakthrough Infectionsa

Valuesb
Demographic characteristics
 Age, mean (SD), range, years 37.8 (13.4), 20.9–77.7
 Male, n (%) 17 (71)
 Race/ethnicity, n (%)
  Asian 2 (8)
  Black 1 (4)
  Hispanic 3 (13)
  Native Hawaiian 1 (4)
  White 17 (71)
Occupational characteristics and military status, n (%)
 Active duty 19 (79)
 Dependent 4 (17)
 Retired 1 (4)
 Healthcare worker 15 (63)
Risk behaviors, n (%)
 Lives with another adult 15 (71)
 Lives with children 7 (50)
 Close contact with person with COVID-19 in past monthc 13 (57)
 Stayed 6 feet away from people in public more than half the time in past month 19 (83)
 Increased frequency of handwashing in the past month 15 (65)
 Wore mask all the time in the past month 19 (83)
Comorbidities, n (%)
 Any comorbidity 8 (33)
 Multiple comorbidities 3 (13)
 Hypertension 4 (17)
 Asthma or chronic obstructive pulmonary disease 3 (13)
 Obesity 2 (8)
 Diabetes 2 (8)
 Chronic kidney disease 2 (8)
 Renal transplant 1 (4)
 History of venous thromboembolism 1 (5)
 Immunosuppressant medication, n (%) 1 (4)
 None 16 (67)
Vaccine product received, n (%)
 BNT162b2 (Pfizer-BioNTech) 22 (92)
 mRNA-1273 (Moderna) 2 (8)
Illness onset from time of final dose,d median (IQR, range), days 50.5 (31.5–73.5, 15–95)
Symptom severity, n (%)
 Never had symptoms 5 (24)
 Mild 7 (33)
 Moderate 6 (29)
 Severe 3 (14)
 Critical 0 (0)
Illness outcomes and other characteristics, n (%)
 Prior SARS-CoV-2 infection 0 (0)
 Hospitalized 0 (0)
 Feeling back to normale 6 (35)
 Days to recovery,f median (range) 5 (0–14)

“None” refers to no comorbidities.

Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

aRestricted to those with illness onset ≥14 days after final dose of vaccination.

bDenominator varies based on response rate.

cBased on the question: “In the month before you were ill, tested for, or exposed to COVID-19, did you have close contact (eg, caring for or living with) a person who tested positive for COVID-19 or had symptoms of COVID-19 such as fever and/or acute respiratory illness?”

dDerived from time to earliest SARS-CoV-2 test positivity in those without symptoms.

eAt time of interview.

fIn those recovered by time of interview (n = 6).

HHS Vulnerability Disclosure